White Plains, NY, United States of America

Marius Ardeleanu

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 6.7

ph-index = 2

Forward Citations = 47(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Marius Ardeleanu: Innovator in Asthma and Skin Infection Treatments

Introduction

Marius Ardeleanu is a notable inventor based in White Plains, NY (US), recognized for his contributions to medical innovations. He holds a total of four patents, focusing on methods for treating asthma and skin infections. His work has significant implications for improving patient care and treatment outcomes.

Latest Patents

Marius Ardeleanu's latest patents include innovative methods for treating or preventing asthma by administering an IL-4R antagonist. This invention provides therapeutic compositions that can effectively address asthma and related conditions in patients. Another significant patent involves methods for treating skin infections by administering an IL-4R antagonist. This invention aims to reduce skin infections, particularly in patients with atopic dermatitis, while also improving skin barrier function and minimizing inflammation due to microbial infections.

Career Highlights

Throughout his career, Marius has worked with prominent companies in the biotechnology sector, including Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in developing groundbreaking medical treatments.

Collaborations

Marius has collaborated with notable professionals in the field, including Neil John Graham and Allen Radin. These partnerships have enhanced his research and development efforts, leading to significant advancements in his areas of focus.

Conclusion

Marius Ardeleanu's innovative work in the medical field, particularly in asthma and skin infection treatments, showcases his dedication to improving healthcare. His patents reflect a commitment to advancing therapeutic options for patients in need.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…